BioLargo 2021 revenue $2.53M (+4%), net loss down 29% to $6.9M, debt cut to $0.68M

BIOLARGO, INC.

Revenue of $2,531,000 for FY2021, a 4% increase from 2020; Q4 revenue $784,000 (+10% QoQ).
Net loss reduced 29% to $6.9M, including $1.9M non-cash option expense and $342K impairment.
Total debt slashed from $2.9M to $681K; total liabilities down from $5.2M to $2.1M.
AEC PFAS treatment passed tests with municipality and federal agency; Garratt-Callahan MLD prototype completed.
Ikigai partnership for pet odor product exceeds initial projections; Clyra's Bioclynse secures two hospital customers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.